DGAP-News: Elanix Biotechnologies AG / Key word(s): Contract/Agreement
PRESS RELEASE Elanix Biotechnologies AG strengthens its sales network by signing an Agreement with MedBioSante, Moscow-Based Distributor for GYNrepair(R) Collaboration with MedBioSante Extends Sales of Advanced Skin Care Products to Russian Market GYNrepair(R) cream, which is developed and marketed by Elanix's wholly-owned subsidiary Repair A, contains a proprietary Cell Free Protein Complex (CFPC(R)), including various proteins, such as collagen and fibronectin, and is perfume-free. It is specifically designed for use on the genital external mucosa to soothe the feeling of discomfort, twinges and dryness. "This collaboration with a Moscow-based specialist distributor is a part of our strategy to increase availability of our advanced skin care products across Europe," said Tomas Svoboda, CEO of Elanix Biotechnologies. "We look forward to making our GYNrepair cream more widely available as we expand on this partnership and extend our reach across Russia and the CIS states." "We are enthusiastic about this new partnership with Elanix Biotechnologies and proud to bring a technology-driven product in the field of gynaecological cosmetics to the Russian market to help meet increasing demand," said Maia Karlovna Filippova-Kokeladze, CEO of MedBioSante. "We are confident this will represent a long-term partnership and greater collaboration in the future." #### Elanix develops and commercializes tissue regeneration products for chronic and acute wound care as well as advanced skin care for dermatological and gynecological applications. Additionally, Elanix provides services in cell therapy and related technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells. Elanix has registered headquarters in Berlin, Germany, with offices in Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more information and updates, visit www.elanixbiotechnologies.com. Follow us on Twitter @elanix_biotech MedBioSante, headquartered in Moscow (Russia) and with a branch in Geneva (Switzerland), provides outsourcing services throughout Russia, CIS and Eastern European countries for pharmaceutical and cosmetic companies. MedBioSante operates in the area of distribution, sales and the promotion of pharmaceutical products, foodstuffs and cosmetics and provides services in the field of certification and registration of medical devices and pharmaceutical products throughout the Russian Federation, CIS and Eastern European countries. Contacts:
23.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Elanix Biotechnologies AG |
Kurfürstendamm 32 | |
10719 Berlin | |
Germany | |
Phone: | +41 22 363 66 40 |
Fax: | +41 22 363 66 41 |
E-mail: | info@elanix-bt.com |
Internet: | www.elanixbiotechnologies.com |
ISIN: | DE000A0WMJQ4 |
WKN: | A0WMJQ |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf |
End of News | DGAP News Service |
688489 23.05.2018